Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

X4 Pharmaceuticals (XFOR) Shares Outstanding (Diluted Average) (2020 - 2025)

X4 Pharmaceuticals' Shares Outstanding (Diluted Average) history spans 6 years, with the latest figure at $42.3 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) rose 531.04% year-over-year to $42.3 million; the TTM value through Dec 2025 reached $42.3 million, up 531.04%, while the annual FY2025 figure was $42.3 million, 531.04% up from the prior year.
  • Shares Outstanding (Diluted Average) reached $42.3 million in Q4 2025 per XFOR's latest filing, down from $43.3 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $197.0 million in Q3 2023 to a low of $5.9 million in Q4 2023.
  • Average Shares Outstanding (Diluted Average) over 5 years is $50.6 million, with a median of $30.2 million recorded in 2021.
  • Peak YoY movement for Shares Outstanding (Diluted Average): crashed 96.6% in 2024, then surged 546.3% in 2025.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $25.7 million in 2021, then skyrocketed by 146.71% to $63.5 million in 2022, then tumbled by 90.67% to $5.9 million in 2023, then rose by 13.08% to $6.7 million in 2024, then skyrocketed by 531.04% to $42.3 million in 2025.
  • Per Business Quant, the three most recent readings for XFOR's Shares Outstanding (Diluted Average) are $42.3 million (Q4 2025), $43.3 million (Q3 2025), and $7.4 million (Q2 2025).